NCT02639026 2025-11-25Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic CancersAbramson Cancer Center at Penn MedicinePhase 1 Completed53 enrolled
NCT04521686 2025-06-27Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 MutationsEli Lilly and CompanyPhase 1 Active not recruiting200 enrolled
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT02649686 2023-08-04Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving TrastuzumabCanadian Cancer Trials GroupPhase 1 Completed15 enrolled
NCT01975831 2022-10-12A Phase 1 Study to Evaluate MEDI4736 in Combination With TremelimumabLudwig Institute for Cancer ResearchPhase 1 Completed104 enrolled 23 charts
NCT03430518 2020-08-05Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian CancerIcahn School of Medicine at Mount SinaiPhase 1 Completed9 enrolled
NCT02586987 2019-11-18A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid TumoursAstraZenecaPhase 1 Completed58 enrolled